Status:
COMPLETED
Kinetics of YKL-40 Protein in Serum of Cystic Fibrosis Patients
Lead Sponsor:
Institut de Recherches Cliniques de Montreal
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
YKL-40 is proposed as a biomarker of various inflammatory disease diabetes and lung disease including cystic fibrosis. In those cross-sectional studies, a unique value of YKL-40 is used to correlate w...
Detailed Description
Observational prospective cohort: The primary objective of the study is to determine if variation of YKL-40 concentration (in blood or sputum) over 24 months will correlate with the biological or clin...
Eligibility Criteria
Inclusion
- man and woman ≥ 18 ans.
- documented CF diagnostic (sweat test or genotype).
- FEV1 ≥ 25%
- Stable: no infection in the last two weeks before the visit.
Exclusion
- 1\. Exacerbation with respiratory symptoms with ou without hospitalization in the last two weeks 2. Exacerbation treated with IV antibiotics. 3. Patients with B. Cepacia
- \-
Key Trial Info
Start Date :
May 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2018
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT02305784
Start Date
May 1 2015
End Date
June 20 2018
Last Update
January 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CRIMontreal
Montreal, Quebec, Canada, H2W 1R7